Clinical Research

A Randomized, open-label, Phase 2 study of the IDO inhibitor INCB024360 versus tamoxifen for subjects with biochemical-recurrent-only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer following complete remission with first-line chemotherapy

Principal Investigator: Michael Goodheart, MD

This study is being done to find out if the experimental drug INCB024360 is safe and has helpful effects when given to women with a certain type of ovarian cancer. Women who have elevated CA-125 (a marker in the blood used to track the disease) and no evidence of disease ("biochemical recurrent only") after achieving complete remission with first-line chemotherapy will be asked to take part. This study will measure how long women who take INCB024360 survive without disease recurrence after study treatment, compared to those that take a hormonal therapy called tamoxifen. About 110 women with biochemical recurrent only ovarian cancer will be participating at approximately 35 study centers.

Cupid 2b: Enzyme Replacement Therapy for Advanced Heart Failure

Principal Investigator:Frances Johnson, MD

A Phase 2b, Double-Blind, Placebo-Controlled, Multinational, Multicenter, Randomized Study Evaluating the Safety and Efficacy of Intracoronary Administration of MYDICAR® (AAV1/SERCA2a) in Subjects With Heart Failure.  The purpose of this trial is to assess whether MYDICAR can reduce the frequency and/or delay heart failure related hospitalizations in persons with advanced heart failure when added to their maximal and optimized therapy.

Please refer to www.clinicaltrials.gov identifier NCT01643330

 for more information.

Effects of Common Anti-inflammatory Drug

Principal Investigator: Gary L. Pierce, PhD

Research Study to Investigate the Effects of a Common Anti-inflammatory Drug on Blood Vessel and Heart Function

Healthy, non-smoking adults age 50-79 years and age18-39 years are invited for a University of Iowa (UI) study of the effects of anti-inflammatory therapy on blood vessel and heart function.  Female participants 50+ years must be postmenopausal for at least one year.
Subjects must be willing to fast for 8 hours prior to testing.

Participants will visit UI's Institute for Clinical and Translational Science Clinical Research Unit 9 times over a 6-7 week period.

Participants will have a variety of cardiovascular measurements and blood samples taken at baseline and then again after taking an aspirin-like drug called Salsalate or a placebo for 4 weeks.

Participants will be compensated for their time.

Please contact Veronica Howsare at (319) 356-0578 for more information.

The Effects of Cannabinoid on Patients

Principal Investigator:Ron Schey, MD

Men and women with non-GERD non-cardiac chest pain are invited to participate in a University of Iowa research study investigating the effects of an investigational medication as a potential treatment for subjects with chest pain not related to heart disease.

The study involves 4 visits with each visit ranging from 30 minutes to 2 hours. The study tests are provided at no cost. Compensation is provided.

Neucardin Trial :Treatment Study for Stable Chronic Heart Failure

Principal Investigator: KellyAnn Light-McGroary, MD

Efficacy and Safety of Human Neuregulin-1 to Treat Stable Chronic Heart Failure (ZS-01-210)

Recombinant human Neuregulin-1 (rhNRG-1, also called ) is a 61 amino acid peptide that acts directly on damaged heart muscle cells to restore their structure and function. This randomized, parallel, placebo-controlled, double-blind, multi-center study will assess the safety and efficacy of rhNRG-1 also known as Neucardin as a treatment for stable chronic heart failure.